AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04858984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: A portable, standalone VR headset called Oculus Go (Facebook Technologies, LLC. 1601 Willow Road, Menlo Park, CA 940250) with a head-mounted display with built in audio drivers was used. Disposable hygiene masks and a surgical cap were used as an underlay below the headset an
Study NCT01969097 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: transcranial direct current stimulation (tDCS)
Study NCT01969097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: transcranial direct current stimulation (tDCS)
Study NCT01969097 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: transcranial direct current stimulation (tDCS)
Study NCT01969097 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor training
Description: Motor training of the affected upper extremity (5 days, 25 min/day).
Study NCT01969097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor training
Description: Motor training of the affected upper extremity (5 days, 25 min/day).
Study NCT01969097 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Motor training
Description: Motor training of the affected upper extremity (5 days, 25 min/day).
Study NCT02678338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hu5F9-G4
Study NCT00657865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramipril
Description: oral intake
Study NCT00657865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02745366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BFPSC+FDBA+PRF
Study NCT02745366 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FDBA+PRF
Study NCT01098812 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis ZCB00 IOL (control)
Description: Tecnis 1-piece acrylic IOL
Study NCT01098812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric Intraocular lens
Description: Toric acrylic intraocular lens with various cylinder powers
Study NCT01017367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDX-1100
Description: MDX-1100 10 mg/kg i.v. over 60 minutes on days 1, 15, 29, 43, 57 and 71
Study NCT01017367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05489692 — intervention group
Intervention type: PROCEDURE
Intervention: hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX)
Description: FOLFOX-HAIC as the following dosage: 130 mg/m2 oxaliplatin infusion for 2 hours; 400 mg/m2 of leucovorin infusion for 2 hours; and 400 mg/ m2 of 5-FU bolus and 1200 of mg/m2 continuous infusion of 5-FU for 23 hours.~Patients received targeted therapy, three different targeted therapy were applied including: 1. lenvatinib 2. sorafenib; 3. apatinib. A portion of patients received PD-1 inhibitor administered intravenously every three weeks.
Study NCT04757441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A: Conventional Treatment + Elongation Longitudinaux Decoaption of Osteo-Articulaire
Description: ELDOA position for L5, S1 level Patient will ask to lie on his back, wedge buttocks in the corner of wall and raise his legs. Then Stretch the legs and push the heels toward ceiling. Extend the spine and stretch the arms above head .~• Patient will hold this position for one minute and repeat it for 4 -5 times.~Conventional treatment will include:~* Hot pack for 15 minutes .~* TENS for 10 minutes .~* self stretching of hamstrings
Study NCT04757441 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group B: Conventional treatment
Description: Participants will receive only conventional treatment which will include:~* Hot pack for 15 minutes .~* TENS for 10 minutes .~* self stretching of hamstrings
Study NCT00376090 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-CMDR
Description: 10\^7 PFU IM, 1.0 mL
Study NCT00376090 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.0 mL IM
Study NCT00376090 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-CMDR
Description: 10\^6 PFU ID, 0.1 mL
Study NCT00376090 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.1 mL ID
Study NCT00376090 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-CMDR
Description: 10\^8 PFU IM, 1.0 mL
Study NCT00376090 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-CMDR
Description: 10\^7 PFD ID, 0.1 mL
Study NCT04262050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS)
Study NCT01200004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m2 subcutaneous or by vein on days 1 - 5 of a 28 day cycle.
Study NCT01200004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.
Study NCT01200004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grifola Frondosa
Description: 3 mg/kg by mouth twice a day on days 1 - 21 of a 28 day cycle.
Study NCT01887951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penthrox Inhaler
Study NCT01887951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol Injection
Study NCT04587011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan dose A or placebo
Description: Tegoprazan A mg or placebo taken orally twice daily for 3 days.
Study NCT04587011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan dose B or placebo
Description: Tegoprazan B mg or placebo taken orally twice daily for 3 days.
Study NCT04587011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan dose C or placebo
Description: Tegoprazan C mg or placebo taken orally twice daily for 3 days.
Study NCT04587011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan dose D or placebo
Description: Tegoprazan D mg or placebo taken orally twice daily for 3 days.
Study NCT01627002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PA401
Description: Part A of Study: Subcutaneous, 0.1mg to 50mg, single ascending doses Part B of Study: Subcutaneous, up to 17.1mg, single dose
Study NCT01627002 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous
Study NCT00210184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan associated to fluorouracil and leucovorin
Study NCT00786747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personally tailored computer program
Description: The experimental computer program provides the user with information about colorectal cancer screening that is tailored to their self-efficacy, readiness, and perceived barriers to undergoing screening, in their preferred language (English or Spanish).
Study NCT00786747 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-tailored control computer program
Description: This program provides users with non-tailored information about colorectal cancer screening, in their preferred language (English or Spanish).
Study NCT01444482 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix M
Description: 1 human dose of seasonal influenza vaccine formulated with 50 µg Matrix M, total dosage volume 0.55 mL injected intramuscularly in the upper arm once at day 0.
Study NCT01444482 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Seasonal influenza vaccine
Description: 1 human dose of seasonal influenza vaccine
Study NCT03427567 — intervention group
Intervention type: PROCEDURE
Intervention: Sublobar dissection
Description: Sublobar dissection plus lymphadenectomy
Study NCT03017638 — intervention group
Intervention type: OTHER
Intervention: Questionaire
Description: Patients undergoing primary laparoscopic colectomy patients under general anesthesia with an additional Quadratus lumborum block (QLB ) will be asked to fill out a questionnaires detailing: numeric verbal analogue scores (VAS) and quality of recovery score(QoR) preoperatively, 24 hours, 48 hour and four weeks after surgery. Additional data will be collected: ASA physical status, demographics, intra- and post operative opiate(expressed as morphine equivalent in mg/kg) and non opiate consumption in order to assess the analgesic efficacy of QLB for primary laparoscopic colectomy. QLB will be performed as per standard routine regimens, in the operating room after induction of general anesthesia and prior to surgery.
Study NCT02463721 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ascitic fluid culture and microbiological testing
Description: ascitic fluid culture and microbiological testing for 100 patients with liver cirrhosis and ascites with suspicion of SBP
Study NCT02700152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UltraShape
Description: Tissue selectivity is achieved by a proprietary knowledge of ultrasound parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
Study NCT03008954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GSP3
Description: Each capsule of GSP3 (previously Attiva) contains 700 mg of a mixture of two food-grade materials: carboxymethylcellulose that is cross-linked with citric acid.
Study NCT03008954 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Avicel (modified Cellulose)
Description: Each capsule of Avicel contains approximately 350 mg of microcrystalline cellulose
Study NCT03008954 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Avicel (modified Cellulose)
Description: Each capsule of Avicel contains approximately 350 mg of microcrystalline cellulose
Study NCT02087072 — intervention group
Intervention type: OTHER
Intervention: Collaborative visit with provider and pharmacist
Study NCT03189862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Skills Intervention
Description: The behavioral motor skills intervention (CHAMP) is an intervention strategy that uniquely addresses differences in children's developmental levels on an individualized basis. CHAMP does not equate to a one size fits all approach. Children will be in an environment that promotes opportunities for them to develop improvements in motor skills based on their specific individual needs and choices. The CHAMP intervention promotes a mastery climate that allows each individual child to be successful and learn while promoting intrinsic motivation and autonomy. CHAMP will be implemented 4x/week for 30 minutes across ≈30 weeks for ≈3000 minutes of intervention time.
Study NCT00164619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VOICES/VOCES
Description: 45-minute intervention for small groups of African American and Hispanic heterosexual men and women. Group members are same gender and race/ethnicity. View culturally-specific condom promotion video. Facilitated group discussion to build skills in condom use and condom negotiation. Education on condom varieties to overcome participants' personal barriers to condoms use. Distribution of 3 specialty condoms of participant's choice (i.e., different sizes, textures, thicknesses, lubrication, material). \[see Brief Summary above\]
Study NCT00164619 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard STD clinic services
Description: Individual physical exam, STD/HIV tests, treatment as indicated
Study NCT03708172 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Intermittent TBS (iTBS) rTMS applied to the left Dorsolateral Prefrontal Cortex (DLPFC) + continuous TBS (cTBS) rTMS applied to the right DLPFC. The order will be counterbalanced. Administration of this treatment takes roughly 10 minutes. This treatment will be applied daily, 5 days/week, for 4 weeks.
Study NCT03708172 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Intermittent TBS (iTBS) rTMS applied to the left Dorsolateral Prefrontal Cortex (DLPFC) + continuous TBS (cTBS) rTMS applied to the right DLPFC. The order will be counterbalanced. Administration of this treatment takes roughly 10 minutes. This treatment will be applied daily, 5 days/week, for 4 weeks.
Study NCT03708172 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Computer-based cognitive training designed to enhance executive function
Study NCT03708172 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham Cognitive Training
Description: Computer-based inactive sham training
Study NCT03109158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC-6004
Description: NC-6004 provided by NanoCarrier
Study NCT03109158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Commercially Available
Study NCT03109158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Commercially Available
Study NCT02126449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting mimicking diet
Study NCT03837704 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IQOS
Description: AAA patients will switch from cigarette smoking to ad libitum IQOS use, with no flavor variant restrictions.
Study NCT03837704 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette
Description: AAA patients will continue to smoke their cigarettes ad libitum, with no brand restrictions.
Study NCT03837704 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation
Description: AAA patients who have completely quit smoking will continue to remain abstinent from smoking cigarettes or using any tobacco or nicotine-containing product(s)
Study NCT03505385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Co-created intervention - Get Ready (GR)
Description: The Get Ready (GR) intervention was delivered one-to-one with the care home resident and a relevant family member during a 12-week period:~1. The familiarisation stage aimed to build a rapport with two long-term achievement goals to sit less and move more with the resident and the family member and consisted of two sessions, one in week 1 (50-60minutes) and the other in week 3 (30-40 minutes).~2. The ramping up stage aimed to review the rapport and reach an achievable consensus with the resident and the family member. It consisted of two sessions, one in week 5 and the other in week 7 (20-30 minutes each).~3. The maintenance stage aimed at integrating behaviours and included two sessions, one in week 9 and the other at week 12 (20-30 minutes each). Sessions 5 and 6 were used to understand how the resident was getting on with their short-term GR goals, facilitating some problem-solving discussions.
Study NCT00718549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Cladribine will be adminiatered at a dose of 0.12 mg/kg/day as IV infusion on Days 2-4 of each 28-day cycle during induction phase.
Study NCT00718549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administred at a dose of 250 mg/m\^2/day as IV infusion over 15-30 minutes on Days 2-4 of each 28-day cycle during induction phase.
Study NCT00718549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered at a dose of 375 mg/m\^2 as IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\^2 as IV infusion on Day 1 of Cycles 2-6 during induction phase. Rituximab will be administered at a dose of 375 mg/m\^2 as IV infusion on Day 1 of each 12-week cycle during maintenance phase.
Study NCT01353508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: 200 mg and 400 mg tablets
Study NCT01353508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: 160 mg tablets
Study NCT01951079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-amniotic injection of DIGOXIN
Study NCT03373981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: repetitive transcranial magnetic stimulation
Study NCT03366051 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Node Mapping
Description: At least one sentinel node should be retrieved in both hemipelvis. If no sentinel node is found in one hemipelvis, a side specific lymphadenectomy will be performed.
Study NCT03366051 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sentinel Node Mapping
Description: At least one sentinel node should be retrieved in both hemipelvis. If no sentinel node is found in one hemipelvis, a side specific lymphadenectomy will be performed.
Study NCT03366051 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lymphadenectomy
Description: Systematic Pelvic and Para-Aortic Lymphadenectomy
Study NCT00701090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: Sitagliptin 100 mg q.d. (q.d. = once daily); Duration of Treatment: 30 weeks
Study NCT00701090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: glimepiride
Description: glimepiride 1 mg per day to be up-titrated (up to week 18 of the double-blind treatment period) as considered appropriate by the investigator, based upon the results of patient's self blood glucose monitoring (SBGM). The maximum dose of glimepiride must not be higher than 6 mg/day.
Study NCT00701090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: open-label metformin
Description: open-label metformin oral tablets (≥1500 mg/day) in addition to Glimepiride or Sitagliptin treatment.
Study NCT00701090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: open-label metformin
Description: open-label metformin oral tablets (≥1500 mg/day) in addition to Glimepiride or Sitagliptin treatment.
Study NCT01576172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate
Description: Given PO
Study NCT01576172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO
Study NCT01576172 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01576172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01576172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO
Study NCT01576172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT01576172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT03623451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Medicine Formula
Description: Chinese Medicine Formula, composed of American ginseng 10g, Poria cocos 15g, bighead atractylodes rhizome 20g, Astragalus mongholicus 30g, Crataegus pinnatifida Bunge 20g, Salvia miltiorrhiza Bge. 20g, Pericarpium Citri Reticulatae 10g will be decocted and packaged into vacuum packs by the pharmaceutical department of First Affiliated Hospital, Heilongjiang University of Chinese Medicine (140 mL/pack). Subjects will take 2 packages per day for three months.
Study NCT00381563 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Patellofemoral realigning knee brace
Description: Knee brace that changes the tracking of the patella over the femur bone
Study NCT00381563 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Non-aligning knee brace
Description: Knee brace that does not change the tracking of the patella over the femur bone
Study NCT04532736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emthexate
Description: After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
Study NCT04532736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednol
Description: After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
Study NCT04532736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate
Description: After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
Study NCT03019250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Colostrum
Description: Enteral colostrum 20g/day powdered colostrum to be mixed in with water and given via nasogastric tube q4 hrs.
Study NCT03019250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin mixed with water given via NG tube Q 4 hours.